BLU-667 - Pralsetinib | RG 6396

Based on 66 reference(s) in Google Scholar 8 10 66

Axon 3854

CAS [2097132-94-8]

MF C27H32FN9O2
MW 533.60

  • Purity: 99%
  • Optical purity: 99%
  • Soluble in DMSO
Recently added

BLU-667

Description

BLU-667 is a highly potent and selective next generation inhibitor of oncogenic RET fusion and activating mutation with IC50s in low nMs for Wt RET, RET mutants V804L, V804M, M918T and CCDC6-RET fusion, displaying broad and robust anti-tumor activity against multiple RET-driven solid tumor types. It is highly active against V804 gatekeeper substitutions that are mKI resistant. In vivo, BLU-667 potently inhibits growth of NSCLC and thyroid cancer xenografts driven by various RET mutations and fusions without inhibiting VEGFR2. In first-in-human testing, BLU-667 significantly inhibited RET signaling and induced durable clinical responses in patients with RET-altered NSCLC and MTC without notable off-target toxicity.

KEYWORDS: BLU-667 | Supplier | RET inhibitor | Pralsetinib | RG 6396 | BLU667 | BLU 667 | RG6396 | RG 6396 | X 581238 | X581238 | CT-BLU667 | CAS [2097132-94-8] | GDNF | RET | Inhibitor | Receptors

Highly potent and selective next generation inhibitor of oncogenic RET fusion and activating mutation

Chemical name

(1s,4R)-N-((S)-1-(6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl)ethyl)-1-methoxy-4-(4-methyl-6-(5-methyl-1H-pyrazol-3-ylamino)pyrimidin-2-yl)cyclohexanecarboxamide

Source information

Sold in collaboration with Chemietek

Parent CAS No.

[2097132-94-8]

The purity of Axon Ligands™ is confirmed by HPLC-MS, 1H-NMR and/or microanalysis. Analytical data are available upon request.

Caution: Axon Ligands™ are not fully tested. They are for research purposes only! Not for human consumption!

Please wait...